Microbot Medical Inc. has achieved a significant milestone by securing its first patent in Japan for the LIBERTY Endovascular Robotic System, a development that underscores the company's commitment to enhancing endovascular procedures. This patent encompasses the core technology of LIBERTY, which features a compact robotic device designed to drive and manipulate surgical tools with precision. The recent patent follows a series of approvals in the U.S., China, and Israel, highlighting the growing international interest in LIBERTY. Harel Gadot, the company's CEO, emphasized the strategic importance of markets like Japan, indicating that the company is poised to leverage its recent FDA clearance to facilitate global expansion and expedite local approvals, thereby addressing a critical gap in optimal care delivery.
The LIBERTY system promises to revolutionize interventional procedures by offering a single-use, compact design that enables remote operation, thereby enhancing procedural precision and safety. Its versatility allows application across neurovascular, cardiovascular, and peripheral vascular procedures, potentially lowering costs while improving care quality. Additionally, Microbot's recent patent for a modular robotic surgical system further positions LIBERTY for broader applications in endovascular procedures. With plans to raise $92 million from stock sales to support development and commercialization efforts, Microbot Medical is strategically aligning itself to capitalize on the burgeoning market for surgical robotics, which is expected to gain traction in the coming years.
